---
document_datetime: 2025-12-02 06:10:25
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/irbesartan-teva.html
document_name: irbesartan-teva.html
version: success
processing_time: 0.170348
conversion_datetime: 2025-12-28 13:47:01.487929
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Irbesartan Teva

[RSS](/en/individual-human-medicine.xml/66451)

##### Authorised

This medicine is authorised for use in the European Union

irbesartan Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Irbesartan Teva](#news-on)
- [More information on Irbesartan Teva](#more-information-on-irbesartan-teva-703)
- [More information on Irbesartan Teva](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach its recommendations on how to use the medicine.

If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis for the CHMP recommendations, read the scientific discussion (also part of the EPAR).

Expand section

Collapse section

## What is Irbesartan Teva?

Irbesartan Teva is a medicine that contains the active substance irbesartan. It is available as white tablets (75, 150 and 300 mg).

Irbesartan Teva is a 'generic medicine'. This means that Irbesartan Teva is similar to a 'reference medicine' already authorised in the European Union (EU) called Aprovel.

## What is Irbesartan Teva used for?

Irbesartan Teva is used in patients who have essential hypertension (high blood pressure). 'Essential' means that the hypertension has no obvious cause. Irbesartan Teva is also used to treat kidney disease in patients with hypertension and type 2 diabetes (non-insulin-dependent diabetes). Irbesartan Teva is not recommended for use in patients below 18 years of age, because of a lack of information on safety and effectiveness in this age group.

The medicine can only be obtained with a prescription.

## How is Irbesartan Teva used?

Irbesartan Teva is taken by mouth, with or without food. The usual recommended dose is 150 mg once a day. If the blood pressure is not sufficiently controlled, the dose can be increased to 300 mg a day or other medicines for hypertension can be added, such as hydrochlorothiazide. A starting dose of 75 mg can be used in patients receiving haemodialysis (a blood clearance technique) or in patients over 75 years of age.

In patients with hypertension and type 2 diabetes, Irbesartan Teva is added to other treatments for hypertension. Treatment is started at 150 mg once a day and is usually increased to 300 mg once a day.

## How does Irbesartan Teva work?

The active substance in Irbesartan Teva, irbesartan, is an 'angiotensin II receptor antagonist', which means that it blocks the action of a hormone in the body called angiotensin II. Angiotensin II is a powerful vasoconstrictor (a substance that narrows blood vessels). By blocking the receptors to which angiotensin II normally attaches, irbesartan stops the hormone having an effect, allowing the blood vessels to widen. This allows the blood pressure to drop, reducing the risks associated with high blood pressure, such as having a stroke.

## How has Irbesartan Teva been studied?

Because Irbesartan Teva is a generic medicine, studies have been limited to tests to determine that it is bioequivalent to the reference medicine, Aprovel. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

## What are the benefit and risk of Irbesartan Teva?

Because Irbesartan Teva is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as the reference medicine.

## Why has Irbesartan Teva been approved?

The Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Irbesartan Teva has been shown to have comparable quality and to be bioequivalent to Aprovel. Therefore, the CHMP's view was that, as for Aprovel, the benefit outweighs the identified risk. The Committee recommended that Irbesartan Teva be given marketing authorisation.

## Other information about Irbesartan Teva

The European Commission granted a marketing authorisation valid throughout the European Union for Irbesartan Teva to Teva Pharma B.V. on 30 October 2009.

Irbesartan Teva : EPAR - Summary for the public

English (EN) (43.36 KB - PDF)

**First published:** 16/11/2009

**Last updated:** 16/11/2009

[View](/en/documents/overview/irbesartan-teva-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-969)

български (BG) (166.76 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

16/11/2009

[View](/bg/documents/overview/irbesartan-teva-epar-summary-public_bg.pdf)

español (ES) (44.96 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

16/11/2009

[View](/es/documents/overview/irbesartan-teva-epar-summary-public_es.pdf)

čeština (CS) (155.17 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

16/11/2009

[View](/cs/documents/overview/irbesartan-teva-epar-summary-public_cs.pdf)

dansk (DA) (44.4 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

16/11/2009

[View](/da/documents/overview/irbesartan-teva-epar-summary-public_da.pdf)

Deutsch (DE) (45.09 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

16/11/2009

[View](/de/documents/overview/irbesartan-teva-epar-summary-public_de.pdf)

eesti keel (ET) (43.89 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

16/11/2009

[View](/et/documents/overview/irbesartan-teva-epar-summary-public_et.pdf)

ελληνικά (EL) (175.67 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

16/11/2009

[View](/el/documents/overview/irbesartan-teva-epar-summary-public_el.pdf)

français (FR) (45.24 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

16/11/2009

[View](/fr/documents/overview/irbesartan-teva-epar-summary-public_fr.pdf)

italiano (IT) (44.58 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

16/11/2009

[View](/it/documents/overview/irbesartan-teva-epar-summary-public_it.pdf)

latviešu valoda (LV) (174.88 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

16/11/2009

[View](/lv/documents/overview/irbesartan-teva-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (152.48 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

16/11/2009

[View](/lt/documents/overview/irbesartan-teva-epar-summary-public_lt.pdf)

magyar (HU) (148.61 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

16/11/2009

[View](/hu/documents/overview/irbesartan-teva-epar-summary-public_hu.pdf)

Malti (MT) (157.94 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

16/11/2009

[View](/mt/documents/overview/irbesartan-teva-epar-summary-public_mt.pdf)

Nederlands (NL) (44.5 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

16/11/2009

[View](/nl/documents/overview/irbesartan-teva-epar-summary-public_nl.pdf)

polski (PL) (164.65 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

16/11/2009

[View](/pl/documents/overview/irbesartan-teva-epar-summary-public_pl.pdf)

português (PT) (44.74 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

16/11/2009

[View](/pt/documents/overview/irbesartan-teva-epar-summary-public_pt.pdf)

română (RO) (148.89 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

16/11/2009

[View](/ro/documents/overview/irbesartan-teva-epar-summary-public_ro.pdf)

slovenčina (SK) (151.74 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

16/11/2009

[View](/sk/documents/overview/irbesartan-teva-epar-summary-public_sk.pdf)

slovenščina (SL) (114.04 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

16/11/2009

[View](/sl/documents/overview/irbesartan-teva-epar-summary-public_sl.pdf)

Suomi (FI) (44.24 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

16/11/2009

[View](/fi/documents/overview/irbesartan-teva-epar-summary-public_fi.pdf)

svenska (SV) (44.22 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

16/11/2009

[View](/sv/documents/overview/irbesartan-teva-epar-summary-public_sv.pdf)

## Product information

Irbesartan Teva : EPAR - Product Information

English (EN) (588.13 KB - PDF)

**First published:** 16/11/2009

**Last updated:** 29/01/2025

[View](/en/documents/product-information/irbesartan-teva-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-463)

български (BG) (742.76 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

29/01/2025

[View](/bg/documents/product-information/irbesartan-teva-epar-product-information_bg.pdf)

español (ES) (609.67 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

29/01/2025

[View](/es/documents/product-information/irbesartan-teva-epar-product-information_es.pdf)

čeština (CS) (689.41 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

29/01/2025

[View](/cs/documents/product-information/irbesartan-teva-epar-product-information_cs.pdf)

dansk (DA) (598.88 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

29/01/2025

[View](/da/documents/product-information/irbesartan-teva-epar-product-information_da.pdf)

Deutsch (DE) (621.02 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

29/01/2025

[View](/de/documents/product-information/irbesartan-teva-epar-product-information_de.pdf)

eesti keel (ET) (558.43 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

29/01/2025

[View](/et/documents/product-information/irbesartan-teva-epar-product-information_et.pdf)

ελληνικά (EL) (724.09 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

29/01/2025

[View](/el/documents/product-information/irbesartan-teva-epar-product-information_el.pdf)

français (FR) (614.5 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

29/01/2025

[View](/fr/documents/product-information/irbesartan-teva-epar-product-information_fr.pdf)

hrvatski (HR) (668.4 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

29/01/2025

[View](/hr/documents/product-information/irbesartan-teva-epar-product-information_hr.pdf)

íslenska (IS) (565.04 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

29/01/2025

[View](/is/documents/product-information/irbesartan-teva-epar-product-information_is.pdf)

italiano (IT) (612.69 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

29/01/2025

[View](/it/documents/product-information/irbesartan-teva-epar-product-information_it.pdf)

latviešu valoda (LV) (676.43 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

29/01/2025

[View](/lv/documents/product-information/irbesartan-teva-epar-product-information_lv.pdf)

lietuvių kalba (LT) (655.39 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

29/01/2025

[View](/lt/documents/product-information/irbesartan-teva-epar-product-information_lt.pdf)

magyar (HU) (658.92 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

29/01/2025

[View](/hu/documents/product-information/irbesartan-teva-epar-product-information_hu.pdf)

Malti (MT) (703.6 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

29/01/2025

[View](/mt/documents/product-information/irbesartan-teva-epar-product-information_mt.pdf)

Nederlands (NL) (543.83 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

29/01/2025

[View](/nl/documents/product-information/irbesartan-teva-epar-product-information_nl.pdf)

norsk (NO) (570.47 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

29/01/2025

[View](/no/documents/product-information/irbesartan-teva-epar-product-information_no.pdf)

polski (PL) (699.39 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

29/01/2025

[View](/pl/documents/product-information/irbesartan-teva-epar-product-information_pl.pdf)

português (PT) (566.01 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

29/01/2025

[View](/pt/documents/product-information/irbesartan-teva-epar-product-information_pt.pdf)

română (RO) (683.28 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

29/01/2025

[View](/ro/documents/product-information/irbesartan-teva-epar-product-information_ro.pdf)

slovenčina (SK) (665.26 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

29/01/2025

[View](/sk/documents/product-information/irbesartan-teva-epar-product-information_sk.pdf)

slovenščina (SL) (631.26 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

29/01/2025

[View](/sl/documents/product-information/irbesartan-teva-epar-product-information_sl.pdf)

Suomi (FI) (575.47 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

29/01/2025

[View](/fi/documents/product-information/irbesartan-teva-epar-product-information_fi.pdf)

svenska (SV) (532.65 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

29/01/2025

[View](/sv/documents/product-information/irbesartan-teva-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000246938 28/01/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Irbesartan Teva : EPAR - All Authorised presentations

English (EN) (39.04 KB - PDF)

**First published:** 16/11/2009

**Last updated:** 30/05/2012

[View](/en/documents/all-authorised-presentations/irbesartan-teva-epar-all-authorised-presentations_en.pdf)

[Other languages (23)](#file-language-dropdown-751)

български (BG) (75.35 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

30/05/2012

[View](/bg/documents/all-authorised-presentations/irbesartan-teva-epar-all-authorised-presentations_bg.pdf)

español (ES) (75.2 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

30/05/2012

[View](/es/documents/all-authorised-presentations/irbesartan-teva-epar-all-authorised-presentations_es.pdf)

čeština (CS) (48.62 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

30/05/2012

[View](/cs/documents/all-authorised-presentations/irbesartan-teva-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (40.67 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

30/05/2012

[View](/da/documents/all-authorised-presentations/irbesartan-teva-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (15.62 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

30/05/2012

[View](/de/documents/all-authorised-presentations/irbesartan-teva-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (26.87 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

30/05/2012

[View](/et/documents/all-authorised-presentations/irbesartan-teva-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (51.79 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

30/05/2012

[View](/el/documents/all-authorised-presentations/irbesartan-teva-epar-all-authorised-presentations_el.pdf)

français (FR) (46.63 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

30/05/2012

[View](/fr/documents/all-authorised-presentations/irbesartan-teva-epar-all-authorised-presentations_fr.pdf)

íslenska (IS) (39.76 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

30/05/2012

[View](/is/documents/all-authorised-presentations/irbesartan-teva-epar-all-authorised-presentations_is.pdf)

italiano (IT) (46.49 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

30/05/2012

[View](/it/documents/all-authorised-presentations/irbesartan-teva-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (74.44 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

30/05/2012

[View](/lv/documents/all-authorised-presentations/irbesartan-teva-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (48.91 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

30/05/2012

[View](/lt/documents/all-authorised-presentations/irbesartan-teva-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (115.28 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

30/05/2012

[View](/hu/documents/all-authorised-presentations/irbesartan-teva-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (75.79 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

30/05/2012

[View](/mt/documents/all-authorised-presentations/irbesartan-teva-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (45.79 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

30/05/2012

[View](/nl/documents/all-authorised-presentations/irbesartan-teva-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (47.92 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

30/05/2012

[View](/no/documents/all-authorised-presentations/irbesartan-teva-epar-all-authorised-presentations_no.pdf)

polski (PL) (29.49 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

30/05/2012

[View](/pl/documents/all-authorised-presentations/irbesartan-teva-epar-all-authorised-presentations_pl.pdf)

português (PT) (49.04 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

30/05/2012

[View](/pt/documents/all-authorised-presentations/irbesartan-teva-epar-all-authorised-presentations_pt.pdf)

română (RO) (69.32 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

30/05/2012

[View](/ro/documents/all-authorised-presentations/irbesartan-teva-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (55.06 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

30/05/2012

[View](/sk/documents/all-authorised-presentations/irbesartan-teva-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (40.98 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

30/05/2012

[View](/sl/documents/all-authorised-presentations/irbesartan-teva-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (50.22 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

30/05/2012

[View](/fi/documents/all-authorised-presentations/irbesartan-teva-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (45.27 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

30/05/2012

[View](/sv/documents/all-authorised-presentations/irbesartan-teva-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Irbesartan Teva Active substance irbesartan International non-proprietary name (INN) or common name irbesartan Therapeutic area (MeSH) Hypertension Anatomical therapeutic chemical (ATC) code C09CA04

### Pharmacotherapeutic group

Agents acting on the renin-angiotensin system

### Therapeutic indication

Treatment of essential hypertension.

Treatment of renal disease in patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen.

## Authorisation details

EMA product number EMEA/H/C/001093

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Teva B.V.

Swensweg 5

Opinion adopted 23/07/2009 Marketing authorisation issued 30/10/2009 Revision 17

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Irbesartan Teva : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (141.87 KB - PDF)

**First published:** 27/04/2010

**Last updated:** 29/01/2025

[View](/en/documents/procedural-steps-after/irbesartan-teva-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Angiotensin-II-receptor antagonists (sartans) : Scientific conclusions - Impact of the Article 5(3) scientific opinion on nitrosamines

Adopted

English (EN) (119.28 KB - PDF)

**First published:** 05/07/2021

[View](/en/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_en.pdf)

[Other languages (22)](#file-language-dropdown-642)

български (BG) (145.18 KB - PDF)

**First published:**

05/07/2021

[View](/bg/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_bg.pdf)

español (ES) (125.85 KB - PDF)

**First published:**

05/07/2021

[View](/es/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_es.pdf)

čeština (CS) (139.02 KB - PDF)

**First published:**

05/07/2021

[View](/cs/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_cs.pdf)

dansk (DA) (126.81 KB - PDF)

**First published:**

05/07/2021

[View](/da/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_da.pdf)

Deutsch (DE) (131.05 KB - PDF)

**First published:**

05/07/2021

[View](/de/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_de.pdf)

eesti keel (ET) (123.85 KB - PDF)

**First published:**

05/07/2021

[View](/et/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_et.pdf)

ελληνικά (EL) (139.5 KB - PDF)

**First published:**

05/07/2021

[View](/el/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_el.pdf)

français (FR) (127.12 KB - PDF)

**First published:**

05/07/2021

[View](/fr/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_fr.pdf)

hrvatski (HR) (142.87 KB - PDF)

**First published:**

05/07/2021

[View](/hr/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_hr.pdf)

italiano (IT) (126.56 KB - PDF)

**First published:**

05/07/2021

[View](/it/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_it.pdf)

latviešu valoda (LV) (147.7 KB - PDF)

**First published:**

05/07/2021

[View](/lv/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_lv.pdf)

lietuvių kalba (LT) (148.34 KB - PDF)

**First published:**

05/07/2021

[View](/lt/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_lt.pdf)

magyar (HU) (137.17 KB - PDF)

**First published:**

05/07/2021

[View](/hu/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_hu.pdf)

Malti (MT) (151.21 KB - PDF)

**First published:**

05/07/2021

[View](/mt/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_mt.pdf)

Nederlands (NL) (127.53 KB - PDF)

**First published:**

05/07/2021

[View](/nl/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_nl.pdf)

polski (PL) (137.7 KB - PDF)

**First published:**

05/07/2021

[View](/pl/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_pl.pdf)

português (PT) (128.87 KB - PDF)

**First published:**

05/07/2021

[View](/pt/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_pt.pdf)

română (RO) (143.59 KB - PDF)

**First published:**

05/07/2021

[View](/ro/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_ro.pdf)

slovenčina (SK) (135.07 KB - PDF)

**First published:**

05/07/2021

[View](/sk/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_sk.pdf)

slovenščina (SL) (149.74 KB - PDF)

**First published:**

05/07/2021

[View](/sl/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_sl.pdf)

Suomi (FI) (125.84 KB - PDF)

**First published:**

05/07/2021

[View](/fi/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_fi.pdf)

svenska (SV) (126.99 KB - PDF)

**First published:**

05/07/2021

[View](/sv/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_sv.pdf)

Angiotensin-II-receptor antagonists (sartans) Article 31 referral - CHMP assessment report - Impact of the Article 5(3) scientific opinion on nitrosamines

Adopted

Reference Number: EMA/47245/2021

English (EN) (362.31 KB - PDF)

**First published:** 02/03/2021

[View](/en/documents/variation-report/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-chmp-assessment-report-impact-article-53-scientific-opinion-nitrosamines_en.pdf)

Irbesartan Teva-H-C-1093-A31-32 : EPAR - Scientific conclusions

English (EN) (99.42 KB - PDF)

**First published:** 12/06/2019

[View](/en/documents/scientific-conclusion/irbesartan-teva-h-c-1093-a31-32-epar-scientific-conclusions_en.pdf)

[Other languages (22)](#file-language-dropdown-169)

български (BG) (136.15 KB - PDF)

**First published:**

12/06/2019

[View](/bg/documents/scientific-conclusion/irbesartan-teva-h-c-1093-a31-32-epar-scientific-conclusions_bg.pdf)

español (ES) (98.31 KB - PDF)

**First published:**

12/06/2019

[View](/es/documents/scientific-conclusion/irbesartan-teva-h-c-1093-a31-32-epar-scientific-conclusions_es.pdf)

čeština (CS) (131.08 KB - PDF)

**First published:**

12/06/2019

[View](/cs/documents/scientific-conclusion/irbesartan-teva-h-c-1093-a31-32-epar-scientific-conclusions_cs.pdf)

dansk (DA) (96.12 KB - PDF)

**First published:**

12/06/2019

[View](/da/documents/scientific-conclusion/irbesartan-teva-h-c-1093-a31-32-epar-scientific-conclusions_da.pdf)

Deutsch (DE) (100.2 KB - PDF)

**First published:**

12/06/2019

[View](/de/documents/scientific-conclusion/irbesartan-teva-h-c-1093-a31-32-epar-scientific-conclusions_de.pdf)

eesti keel (ET) (94.4 KB - PDF)

**First published:**

12/06/2019

[View](/et/documents/scientific-conclusion/irbesartan-teva-h-c-1093-a31-32-epar-scientific-conclusions_et.pdf)

ελληνικά (EL) (142.79 KB - PDF)

**First published:**

12/06/2019

[View](/el/documents/scientific-conclusion/irbesartan-teva-h-c-1093-a31-32-epar-scientific-conclusions_el.pdf)

français (FR) (97.56 KB - PDF)

**First published:**

12/06/2019

[View](/fr/documents/scientific-conclusion/irbesartan-teva-h-c-1093-a31-32-epar-scientific-conclusions_fr.pdf)

hrvatski (HR) (125.02 KB - PDF)

**First published:**

12/06/2019

[View](/hr/documents/scientific-conclusion/irbesartan-teva-h-c-1093-a31-32-epar-scientific-conclusions_hr.pdf)

italiano (IT) (95.54 KB - PDF)

**First published:**

12/06/2019

[View](/it/documents/scientific-conclusion/irbesartan-teva-h-c-1093-a31-32-epar-scientific-conclusions_it.pdf)

latviešu valoda (LV) (130.68 KB - PDF)

**First published:**

12/06/2019

[View](/lv/documents/scientific-conclusion/irbesartan-teva-h-c-1093-a31-32-epar-scientific-conclusions_lv.pdf)

lietuvių kalba (LT) (130.84 KB - PDF)

**First published:**

12/06/2019

[View](/lt/documents/scientific-conclusion/irbesartan-teva-h-c-1093-a31-32-epar-scientific-conclusions_lt.pdf)

magyar (HU) (119.82 KB - PDF)

**First published:**

12/06/2019

[View](/hu/documents/scientific-conclusion/irbesartan-teva-h-c-1093-a31-32-epar-scientific-conclusions_hu.pdf)

Malti (MT) (133.78 KB - PDF)

**First published:**

12/06/2019

[View](/mt/documents/scientific-conclusion/irbesartan-teva-h-c-1093-a31-32-epar-scientific-conclusions_mt.pdf)

Nederlands (NL) (99.3 KB - PDF)

**First published:**

12/06/2019

[View](/nl/documents/scientific-conclusion/irbesartan-teva-h-c-1093-a31-32-epar-scientific-conclusions_nl.pdf)

polski (PL) (130.65 KB - PDF)

**First published:**

12/06/2019

[View](/pl/documents/scientific-conclusion/irbesartan-teva-h-c-1093-a31-32-epar-scientific-conclusions_pl.pdf)

português (PT) (96.47 KB - PDF)

**First published:**

12/06/2019

[View](/pt/documents/scientific-conclusion/irbesartan-teva-h-c-1093-a31-32-epar-scientific-conclusions_pt.pdf)

română (RO) (128.25 KB - PDF)

**First published:**

12/06/2019

[View](/ro/documents/scientific-conclusion/irbesartan-teva-h-c-1093-a31-32-epar-scientific-conclusions_ro.pdf)

slovenčina (SK) (119.14 KB - PDF)

**First published:**

12/06/2019

[View](/sk/documents/scientific-conclusion/irbesartan-teva-h-c-1093-a31-32-epar-scientific-conclusions_sk.pdf)

slovenščina (SL) (124.14 KB - PDF)

**First published:**

12/06/2019

[View](/sl/documents/scientific-conclusion/irbesartan-teva-h-c-1093-a31-32-epar-scientific-conclusions_sl.pdf)

Suomi (FI) (97.12 KB - PDF)

**First published:**

12/06/2019

[View](/fi/documents/scientific-conclusion/irbesartan-teva-h-c-1093-a31-32-epar-scientific-conclusions_fi.pdf)

svenska (SV) (96.85 KB - PDF)

**First published:**

12/06/2019

[View](/sv/documents/scientific-conclusion/irbesartan-teva-h-c-1093-a31-32-epar-scientific-conclusions_sv.pdf)

Angiotensin-II-receptor antagonists (sartans) Article 31 referral - CHMP assessment report

Adopted

Reference Number: EMA/217823/2019

English (EN) (531.32 KB - PDF)

**First published:** 02/05/2019

[View](/en/documents/variation-report/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-chmp-assessment-report_en.pdf)

Irbesartan Teva-H-C-1093-A31-17 : EPAR - Scientific conclusions, grounds for variation to the terms of the marketing authorisations and detailed explanation of the scientific grounds for the differences from the PRAC recommendation

English (EN) (48.81 KB - PDF)

**First published:** 01/10/2014

**Last updated:** 01/10/2014

[View](/en/documents/scientific-conclusion/irbesartan-teva-h-c-1093-a31-17-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendation_en.pdf)

[Other languages (22)](#file-language-dropdown-551)

български (BG) (87.49 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/bg/documents/scientific-conclusion/irbesartan-teva-h-c-1093-a31-17-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendation_bg.pdf)

español (ES) (50.51 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/es/documents/scientific-conclusion/irbesartan-teva-h-c-1093-a31-17-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendation_es.pdf)

čeština (CS) (82.81 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/cs/documents/scientific-conclusion/irbesartan-teva-h-c-1093-a31-17-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendation_cs.pdf)

dansk (DA) (49.01 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/da/documents/scientific-conclusion/irbesartan-teva-h-c-1093-a31-17-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendation_da.pdf)

Deutsch (DE) (53.54 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/de/documents/scientific-conclusion/irbesartan-teva-h-c-1093-a31-17-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendation_de.pdf)

eesti keel (ET) (50.6 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/et/documents/scientific-conclusion/irbesartan-teva-h-c-1093-a31-17-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendation_et.pdf)

ελληνικά (EL) (89.54 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/el/documents/scientific-conclusion/irbesartan-teva-h-c-1093-a31-17-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendation_el.pdf)

français (FR) (51.91 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/fr/documents/scientific-conclusion/irbesartan-teva-h-c-1093-a31-17-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendation_fr.pdf)

hrvatski (HR) (80.12 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/hr/documents/scientific-conclusion/irbesartan-teva-h-c-1093-a31-17-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendation_hr.pdf)

italiano (IT) (51.13 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/it/documents/scientific-conclusion/irbesartan-teva-h-c-1093-a31-17-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendation_it.pdf)

latviešu valoda (LV) (81.63 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/lv/documents/scientific-conclusion/irbesartan-teva-h-c-1093-a31-17-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendation_lv.pdf)

lietuvių kalba (LT) (82.54 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/lt/documents/scientific-conclusion/irbesartan-teva-h-c-1093-a31-17-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendation_lt.pdf)

magyar (HU) (68.7 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/hu/documents/scientific-conclusion/irbesartan-teva-h-c-1093-a31-17-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendation_hu.pdf)

Malti (MT) (84.23 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/mt/documents/scientific-conclusion/irbesartan-teva-h-c-1093-a31-17-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendation_mt.pdf)

Nederlands (NL) (49.82 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/nl/documents/scientific-conclusion/irbesartan-teva-h-c-1093-a31-17-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendation_nl.pdf)

polski (PL) (83.62 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/pl/documents/scientific-conclusion/irbesartan-teva-h-c-1093-a31-17-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendation_pl.pdf)

português (PT) (49.74 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/pt/documents/scientific-conclusion/irbesartan-teva-h-c-1093-a31-17-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendation_pt.pdf)

română (RO) (88.19 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/ro/documents/scientific-conclusion/irbesartan-teva-h-c-1093-a31-17-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendation_ro.pdf)

slovenčina (SK) (81.5 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/sk/documents/scientific-conclusion/irbesartan-teva-h-c-1093-a31-17-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendation_sk.pdf)

slovenščina (SL) (79.79 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/sl/documents/scientific-conclusion/irbesartan-teva-h-c-1093-a31-17-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendation_sl.pdf)

Suomi (FI) (49.15 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/fi/documents/scientific-conclusion/irbesartan-teva-h-c-1093-a31-17-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendation_fi.pdf)

svenska (SV) (50.18 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/sv/documents/scientific-conclusion/irbesartan-teva-h-c-1093-a31-17-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendation_sv.pdf)

Irbesartan Teva-H-C-1093-A31-17 : EPAR - Assessment Report - Article 31

Adopted

Reference Number: EMA/PRAC/294920/2014

English (EN) (301.42 KB - PDF)

**First published:** 01/10/2014

**Last updated:** 01/10/2014

[View](/en/documents/variation-report/irbesartan-teva-h-c-1093-a31-17-epar-assessment-report-article-31_en.pdf)

## Initial marketing authorisation documents

Irbesartan Teva : EPAR - Public assessment report

English (EN) (350.66 KB - PDF)

**First published:** 16/11/2009

**Last updated:** 16/11/2009

[View](/en/documents/assessment-report/irbesartan-teva-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Irbesartan Teva

Reference Number: EMEA/CHMP/456015/2009

English (EN) (32.94 KB - PDF)

**First published:** 23/07/2009

**Last updated:** 23/07/2009

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-irbesartan-teva_en.pdf)

#### News on Irbesartan Teva

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13-16 May 2013](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-13-16-may-2013) 17/05/2013

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 October 2011](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-october-2011) 21/10/2011

[European Medicines Agency concludes that benefit-risk balance of angiotensin-II-receptor antagonists remains positive](/en/news/european-medicines-agency-concludes-benefit-risk-balance-angiotensin-ii-receptor-antagonists-remains-positive) 20/10/2011

#### More information on Irbesartan Teva

- [Renin-angiotensin-system (RAS)-acting agents: Article-31 referral](/en/medicines/human/referrals/renin-angiotensin-system-ras-acting-agents)

Questions and answers on the review of angiotensin-II-receptor antagonists and the risk of cancer

Reference Number: EMA/CHMP/834168/2011

English (EN) (511.41 KB - PDF)

**First published:** 20/10/2011

**Last updated:** 11/05/2017

[View](/en/documents/opinion-any-scientific-matter/questions-answers-review-angiotensin-ii-receptor-antagonists-risk-cancer_en.pdf)

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-211)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### More information on Irbesartan Teva

- [Renin-angiotensin-system (RAS)-acting agents - referral](/en/medicines/human/referrals/renin-angiotensin-system-ras-acting-agents)
- [Angiotensin-II-receptor antagonists (sartans) containing a tetrazole group - referral](/en/medicines/human/referrals/angiotensin-ii-receptor-antagonists-sartans-containing-tetrazole-group)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 29/01/2025

## Share this page

[Back to top](#main-content)